NCT05087563 is a NA clinical trial of Neurolens spectacle lens in Binocular Vision Disorder, sponsored by Neurolens Inc..

Who is sponsoring NCT05087563?

NCT05087563 is sponsored by Neurolens Inc..

What drugs are being tested in NCT05087563?

Interventions in NCT05087563: Neurolens spectacle lens, Placebo spectacle lens.

What condition does NCT05087563 study?

NCT05087563 studies Binocular Vision Disorder, Convergence Insufficiency, Computer Vision Syndrome.

Is NCT05087563 still recruiting?

NCT05087563 is currently terminated. Last updated 13 October 2023.

Last reviewed 2023-10-13 · How we verify

NCT05087563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurolens Convergence Insufficiency Study

Terminated NA Last updated 13 October 2023

What this trial tests

NA trial testing Neurolens spectacle lens in Binocular Vision Disorder in 50 participants. Terminated before completion.

Timeline

22 November 2021

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	Neurolens Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	50
Start date	22 November 2021
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	9 locations across United States

Drugs / interventions tested

Neurolens spectacle lens
Placebo spectacle lens

Conditions studied

Binocular Vision Disorder — all drugs for Binocular Vision Disorder →
Convergence Insufficiency — all drugs for Convergence Insufficiency →
Computer Vision Syndrome — all drugs for Computer Vision Syndrome →

Sponsor

Neurolens Inc.

Who can join

Adults 18 to 60, any sex, with Binocular Vision Disorder or Convergence Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Convergence Insufficiency. It is a Prospective randomized double masked two arm performed on a minimum of 100 to a maximum of 150 subjects identified as symptomatic (CISS questionnaire score equal to or greater than 16) done across 3-10 clinical sites. There are two subgroups: a minimum of 50 in each subgroup(subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects(41-60 years).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neurolens spectacle lens

Trials testing the same drug.

NCT05070767 — Neurolens Headache Study · NA · completed

Other Neurolens Inc. trials

Trials by the same sponsor.

NCT05070767 — Neurolens Headache Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05087563 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurolens Inc.
Last refreshed: 13 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05087563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing